News / American Regent
Shirley, NY — American Regent today announced the launch and availability of Fomepizole Injection, AP rated and therapeutically equivalent to Antizol®.
The program offers fellowships in both Medical Affairs & Pharmaceutical Marketing and in Clinical Research & Development.
Shirley, NY — American Regent today announced the launch of Hydroxyprogesterone Caproate Injection, USP, the only preservative free generic alternative to Makena®.
Shirley, NY — American Regent today announced the introduction of Neostigmine Methylsulfate Injection, USP. Product is available for immediate shipment and customers can order through their wholesaler/distributor or by contacting our Customer Support Group at 1-800-645-1706.
Shirley, NY — American Regent today announced the launch of 10% Calcium Chloride Injection, USP. 10% Calcium Chloride Injection, USP is available for immediate shipment. Customers can order 10% Calcium Chloride Injection, USP through their wholesaler/distributor or by contacting our Customer Support Group at 1-800-645-1706.
Shirley, NY — American Regent today announced the launch of Methocarbamol Injection, USP. Methocarbamol Injection, USP is available for immediate shipment. Customers can order Methocarbamol Injection, USP through their wholesaler/distributor or by contacting our Customer Support Group at 1-800-645-1706.
Shirley, NY — American Regent today announced the introduction of Dicyclomine Hydrochloride Injection, USP. Dicyclomine Hydrochloride Injection, USP is available for immediate shipment. Customers can order Dicyclomine Hydrochloride Injection, USP through their wholesaler/distributor or by contacting our Customer Support Group at 1-800-645-1706.
Shirley, NY — American Regent today announced the reintroduction of Hydroxyzine HCl Injection, USP. Hydroxyzine HCl Injection, USP is available for immediate shipment. Customers can order Hydroxyzine HCl Injection, USP through their wholesaler/distributor or by contacting our Customer Support Group at 1-800-645-1706.
Shirley, NY — American Regent, a member of the Daiichi Sankyo Group, announced that the first patient has been enrolled into the phase 3 clinical trial, HEART-FID. This double-blind, multicenter, prospective, randomized, placebo-controlled study will assess the efficacy and safety of iron therapy using intravenous (IV) ferric carboxymaltose (FCM), relative to placebo, in the treatment of patients with heart failure, iron deficiency and a reduced ejection fraction.
Shirley, NY — American Regent today announced the launch of Busulfan Injection, which had been previously approved by the U.S. Food and Drug Administration.